Shobha V, et al. - Experts presented the data on incidence of Tuberculosis (TB) in relation to biologic used for managing autoimmune inflammatory rheumatic diseases (AIRDs), screening test and TB prophylaxis in a real-world setting. Findings suggested the importance of close monitoring of patients receiving biologics in early identification of adverse events, especially in test negative patients. In patients positive for screening, the risk of developing TB could be effectively reduced by the prophylaxis. They noted a greater likeliness of the patients on anti-tumor necrosis factor to develop TB. The likelihood of developing TB increased by 1.5 and 4.6 times, respectively with the presence of comorbidities and steroid.